Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jae-Lyun | - |
dc.contributor.author | Park, Se Hoon | - |
dc.contributor.author | Koh, Su-Jin | - |
dc.contributor.author | Lee, Se Hoon | - |
dc.contributor.author | Kim, Yu Jung | - |
dc.contributor.author | Choi, Yoon Ji | - |
dc.contributor.author | Lee, Jihye | - |
dc.contributor.author | Lim, Ho Yeong | - |
dc.date.accessioned | 2021-09-05T03:19:12Z | - |
dc.date.available | 2021-09-05T03:19:12Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-11 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/96853 | - |
dc.description.abstract | To report the efficacy and safety of using cabazitaxel plus prednisolone chemotherapy to treat Korean patients with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel therapy. This cohort study enrolled 26 mCRPC patients. Treatment consisted of 25 mg/m(2) cabazitaxel that was intravenously administered every 3 weeks, in addition to twice-daily 5 mg prednisolone. The median patient age was 67 years (range = 53-82), median Eastern Cooperative Oncology Group performance status was 1 (range = 0-2), Gleason score was a parts per thousand yen8 in 25 patients (96 %), and median serum prostate-specific antigen (PSA) was 95.3 ng/mL (interquartile range = 9.1-297.7). A total of 180 treatment cycles were administered, and a median of five cycles were administered per patient (range = 1-23). A PSA response was observed in 32 % of evaluable patients. Tumor response was evaluated in eight patients, and three and four patients achieved partial response and stable disease, respectively. Over a median follow-up duration of 23.4 months (95 % CI 11.1-35.6), median time to treatment failure was 4.2 months (95 % CI 1.8-6.6) and median time to progression was 8.5 months (95 % CI 3.0-13.1). Median overall survival was 16.5 months (95 % CI 12.1-20.9). Grade 3 or worse febrile neutropenia developed in eight patients (31 %) and neutropenic infection in four patients (15 %). Cabazitaxel plus prednisolone chemotherapy can be used to treat Korean mCRPC patients. Prophylactic growth factor support should be considered for patients at high risk of neutropenic fever or infection. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | ADVANCED SOLID TUMORS | - |
dc.subject | CELL LUNG-CANCER | - |
dc.subject | CLINICAL-TRIALS | - |
dc.subject | PHASE-I | - |
dc.subject | INCREASED SURVIVAL | - |
dc.subject | WORKING GROUP | - |
dc.subject | END-POINTS | - |
dc.subject | DOCETAXEL | - |
dc.subject | MITOXANTRONE | - |
dc.subject | RECOMMENDATIONS | - |
dc.title | Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Yoon Ji | - |
dc.identifier.doi | 10.1007/s00280-014-2579-5 | - |
dc.identifier.scopusid | 2-s2.0-84919907061 | - |
dc.identifier.wosid | 000344324200012 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.74, no.5, pp.1005 - 1013 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.title | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.volume | 74 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1005 | - |
dc.citation.endPage | 1013 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ADVANCED SOLID TUMORS | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | CLINICAL-TRIALS | - |
dc.subject.keywordPlus | PHASE-I | - |
dc.subject.keywordPlus | INCREASED SURVIVAL | - |
dc.subject.keywordPlus | WORKING GROUP | - |
dc.subject.keywordPlus | END-POINTS | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | MITOXANTRONE | - |
dc.subject.keywordPlus | RECOMMENDATIONS | - |
dc.subject.keywordAuthor | Castration-resistant prostate cancer | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Cabazitaxel | - |
dc.subject.keywordAuthor | Prednisolone | - |
dc.subject.keywordAuthor | Febrile neutropenia | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.